Flow MRI in Normal Pressure Hydrocephalus (HydroFlux)

August 9, 2018 updated by: Centre Hospitalier Universitaire, Amiens

Benefit of Flow Magnetic Resonance Imaging in the Management of Normal Pressure Hydrocephalus

Normal pressure hydrocephalus diagnosis based on quantitative study of cerebro-spinal fluid and blood flow by phase contrast magnetic resonance imaging.

Study Overview

Status

Unknown

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

144

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nord Pas De Calais
      • Lille, Nord Pas De Calais, France, 59000
        • CHU Lille
    • Picardie
      • Amiens, Picardie, France, 80054
        • CHU Amiens

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Ventricular dilation seen on morphological magnetic resonance imaging (MRI)
  • Walking disorder
  • Cognitive disorder
  • Participants gave their written informed consent

Exclusion Criteria:

  • Contra-indication to MRI
  • Obstructive tumoral hydrocephalus
  • Curatorship or tutorship
  • Pregnancy or lactation
  • No social assurance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Surgery
Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)

Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.

Clinical examination consists in Larson's score and MMSE

Other Names:
  • Flow MRI
  • Cine phase-constrast magnetic resonance imaging
  • CSF pulsatility
  • Hydrodynamic
  • Cerebral blood flow
Experimental: Clinical follow-up
Patients who will undergo flow imaging but not surgery (75% of the studied population)

Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.

Clinical examination consists in Larson's score and MMSE

Other Names:
  • Flow MRI
  • Cine phase-constrast magnetic resonance imaging
  • CSF pulsatility
  • Hydrodynamic
  • Cerebral blood flow

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cerebrospinal fluid (CSF) stroke volume evolution other 6 months
Time Frame: Day 1 (baseline), Day 180
Measurement of cerebrospinal fluid (CSF) stroke volume via flow MRI at the Sylvius' aqueduct, pontine cistern and spinal spaces levels and determination of its evolution
Day 1 (baseline), Day 180

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood flow analysis : evolution other 6 months
Time Frame: Day 1 (baseline), Day 180
Assessment of arterial (internal carotids and cerebral arteries) and venous (sagittal sinus, straight sinus) blood flow in terms of mean cerebral blood outflow and stroke volume and determination of blood flow evolution.
Day 1 (baseline), Day 180
Larson's score evolution over 6 months
Time Frame: Day 1, Day 180
Record symptoms on walking, living conditions and urinary disorders
Day 1, Day 180
Neuropsychological test evolution over 6 months
Time Frame: Day1, Day 180
Consists in mini mental status evaluation (MMSE) for cognitive evaluation
Day1, Day 180
Blood flow analysis : evolution other one year
Time Frame: Day 1 (baseline) and Day 365
Assessment of arterial (internal carotids and cerebral arteries) and venous (sagittal sinus, straight sinus) blood flow in terms of mean cerebral blood outflow and stroke volume and determination of blood flow evolution.
Day 1 (baseline) and Day 365
Larson's score evolution over one year
Time Frame: Day 1 and Day 365
Record symptoms on walking, living conditions and urinary disorders
Day 1 and Day 365
Neuropsychological test evolution over one year
Time Frame: Day1, Day 365
Consists in mini mental status evaluation (MMSE) for cognitive evaluation
Day1, Day 365
cerebrospinal fluid (CSF) stroke volume evolution other one year
Time Frame: Day1 (baseline), Day 365
Measurement of cerebrospinal fluid (CSF) stroke volume via flow MRI at the Sylvius' aqueduct, pontine cistern and spinal spaces levels and determination of its evolution
Day1 (baseline), Day 365

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Olivier Balédent, PhD, CHU Amiens

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 3, 2012

Primary Completion (Anticipated)

September 1, 2018

Study Completion (Anticipated)

September 1, 2018

Study Registration Dates

First Submitted

May 24, 2013

First Submitted That Met QC Criteria

July 25, 2013

First Posted (Estimate)

July 29, 2013

Study Record Updates

Last Update Posted (Actual)

August 10, 2018

Last Update Submitted That Met QC Criteria

August 9, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • PHRCIR11-DR-BALEDENT
  • 2011-A01633-38 (Registry Identifier: RCB)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Normal Pressure Hydrocephalus

Clinical Trials on Flow imaging

3
Subscribe